Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
Open Access
- 19 January 2023
- journal article
- research article
- Published by Wiley in Contact Dermatitis
- Vol. 88 (5) , 351-362
Abstract
Background: Real‐world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.Objectives: To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.Methods: This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib‐treated patients. Adverse events were monitored during each visit.Results: Thirty‐eight patients were included, of which 32 patients had HE. At Week 16, EASI‐75 was achieved by 50.0%. Absolute cutoff score NRS‐pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT <7 by 68.8%, and PGAD rating of at least ‘good’ by 53.1%. HECSI‐75 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub‐analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials.Conclusions: Upadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non‐atopic individuals.Keywords
Funding Information
- Pfizer
- Sanofi
This publication has 50 references indexed in Scilit:
- Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic PruritusActa Dermato-Venereologica, 2012
- Hand eczema and quality of life: a population-based studyBritish Journal of Dermatology, 2009
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- How Many Imputations are Really Needed? Some Practical Clarifications of Multiple Imputation TheoryPrevention Science, 2007
- Review: A gentle introduction to imputation of missing valuesJournal of Clinical Epidemiology, 2006
- Construction and validation of a photographic guide for assessing severity of chronic hand dermatitisBritish Journal of Dermatology, 2005
- The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliabilityBritish Journal of Dermatology, 2005
- The Patient-Oriented Eczema MeasureArchives of Dermatology, 2004
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994